Actively Recruiting
Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
Led by University Medical Center Goettingen · Updated on 2024-07-29
500
Participants Needed
1
Research Sites
258 weeks
Total Duration
On this page
Sponsors
U
University Medical Center Goettingen
Lead Sponsor
C
Charite University, Berlin, Germany
Collaborating Sponsor
AI-Summary
What this Trial Is About
The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.
CONDITIONS
Official Title
Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological diagnosis of DLBCL and LBCL
- Planned treatment with guideline-based first-line therapy
- Patient's consent to participate
- All genders, patient age 18 years or older
- Ability to provide informed consent
You will not qualify if you...
- Treatment with R-CHOP or similar regimens already started
- Relationship of dependence or direct employment with the investigator
- Active HIV infection
- Presence or history of other active cancers except basal cell carcinoma of the skin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Universitätsmedizin Göttingen
Göttingen, Lower Saxony, Germany, 37075
Actively Recruiting
Research Team
A
Anna-Carina Hund
CONTACT
G
Gerald Wulf
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here